38. Stevens-Johnson syndrome Clinical trials / Disease details


Clinical trials : 13 Drugs : 23 - (DrugBank : 9) / Drug target genes : 15 - Drug target pathways : 101

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003544-83-FR
(EUCTR)
16/03/202108/01/2021Evaluation de l’efficacité thérapeutique du filgrastim dans les allergies sévères bulleuses aux médicaments s’exprimant sous forme de Lyell et Stevens-Johnson Etude GNETEvaluation de l’efficacité thérapeutique du filgrastim dans les allergies sévères bulleuses aux médicaments s’exprimant sous forme de Lyell et Stevens-Johnson Etude GNET Syndrome de Stevens Johnson (SJS)Syndrome de Lyell (NET)
MedDRA version: 20.1;Level: LLT;Classification code 10042030;Term: Stevens Johnson syndrome;System Organ Class: 100000004858
MedDRA version: 20.0;Classification code 10025166;Term: Lyell syndrome;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: ZARZIO
INN or Proposed INN: FILGRASTIM
Hospices Civils de Lyon - Direction de la Recherche CliniqueNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Phase 2;Phase 3France